Medtronic plc. (NYSE:MDT) shares are trading higher on Monday. The company announced a few new developments amid the stock’s continued uptrend.
What To Know: Medtronic stock has trended higher since November, a move which was headed by gains following better-than-expected second-quarter results and increased full-year 2024 guidance.
Shares extended their uptrend in December, a month which saw several developments for Medtronic, including the company receiving approval by the United States Food and Drug Administration (FDA) for the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of paroxysmal and persistent atrial fibrillation (AF).
On Monday, the company announced CE (Conformité Européenne) Mark approval for the MiniMed 780G system with Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM) which does not require a fingerstick or overtape.
Additionally, Medtronic announced that it received FDA approval of its Percept RC Deep Brain Stimulation (DBS) system.
Shares rose over 2.5% on Monday, adding to the stock’s roughly 20% gain over the past two months.
Related Link: Optimism for Fiserv: Analyst Predicts Robust Growth in Merchant Solutions, Upgrades Stock
MDT Price Action: Shares of MDT were up 2.48% at $86.67 at the time of publication, according to Benzinga Pro.
Image by Parentingupstream from Pixabay
